Tentative Biosimilar Approvals A Consideration for the US FDA

 
• By Derrick Gingery

Concept could help sponsors who reach approvability but must wait several years before reference product exclusivity expires.

Syringe in vial
The FDA is working on several other biosimilar policy areas, including labeling and interchangeability. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics